Thrombosis Journal

Papers
(The H4-Index of Thrombosis Journal is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis62
Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta‐analysis48
Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory45
Coagulation abnormalities in SARS-CoV-2 infection: overexpression tissue factor43
Direct oral anticoagulant use in left ventricular thrombus40
Thrombosis in COVID-19 infection: Role of platelet activation-mediated immunity36
Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis34
Disseminated intravascular coagulation: new identity as endotheliopathy-associated vascular microthrombotic disease based on in vivo hemostasis and endothelial molecular pathogenesis32
Tranexamic acid for the prevention and treatment of bleeding in surgery, trauma and bleeding disorders: a narrative review29
Proximal deep vein thrombosis and pulmonary embolism in COVID-19 patients: a systematic review and meta-analysis28
Possible involvement of Syndecan-1 in the state of COVID-19 related to endothelial injury22
Viscoelastometry for detecting oral anticoagulants22
Fatal pulmonary arterial thrombosis in a COVID-19 patient, with asymptomatic history, occurred after swab negativization22
Complement C5a induces the generation of neutrophil extracellular traps by inhibiting mitochondrial STAT3 to promote the development of arterial thrombosis21
NETosis and SARS-COV-2 infection related thrombosis: a narrative review20
Coagulopathy associated with COVID-19 – Perspectives & Preventive strategies using a biological response modifier Glucan20
Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-1920
Current status of treatment of cancer-associated venous thromboembolism19
High rate of bleeding and arterial thrombosis in COVID-19: Saudi multicenter study18
0.022572994232178